

Catalytic Enantioselective Synthesis of Tetrasubstituted Chromanones via Palladium-Catalyzed Asymmetric Conjugate Arylation Using Chiral Pyridine-Dihydroisoquinoline (PyDHIQ) Ligands

Doohyun Baek, Huijeong Ryu, Ji Yeon Ryu, Junseong Lee, Brian M. Stoltz*, and Sukwon Hong*

Table of Contents


1. General Remarks.....	S2
2. Additional Screening Data and Unsuccessful Substrates.....	S3
3. Ligand Synthesis and Compound Characterization.....	S4
4. Experimental Procedures and Compound Characterization.....	S8
5. References.....	S26
6. X-Ray Analysis for Compound 6e and [(S)- 3d]PdCl ₂	S27
7. NMR Spectra for Compounds.....	S35

1. General Remarks


Unless otherwise specified, all reactions were performed in inert atmosphere with high purity argon (99.999%). Tetrahydrofuran (THF), dichloromethane (CH_2Cl_2), and diethyl ether (Et_2O) were dried under positive pressure of high purity nitrogen (99.999%) using a J. C. Meyer Solvent Purification System prior to use. Commercially available HPLC grade water (H_2O) from fisher chemical was used. 2-substituted chromone derivatives were synthesized according to literature procedure.¹ Naphthalene was purified by sublimation and 4-dimethylaminopyridine (DMAP) was recrystallized in toluene prior to use. All other chemicals including arylboronic acids were purchased from commercial sources (Sigma-Aldrich Co., Alfa Aesar, TCI and Acros Organics) and were used as received without further purification. Reaction temperature was controlled by IKA ETS-D5 temperature controller with IKA hotplate stirrer C-MAG HS7. Hamilton 700 series glass microliter syringes were used to measure amount of H_2O . High purity O_2 (99.995%) was used to make O_2 balloon. Racemic samples were prepared by employing 2,2'-bipyridine as a (*N,N*)-ligand. Thin-layer chromatography (TLC) was performed using Merck silica gel 60 F254 precoated plates and visualized by UV fluorescence quenching, *p*-anisaldehyde, or iodine staining. Merck silica gel 60 (particle size 40–63 nm) was used for flash chromatography. Nuclear magnetic resonance (NMR) spectra were recorded on a JEOL spectrometer, operating at 400 MHz for ^1H NMR, at 101 MHz for ^{13}C NMR and at 376 MHz for ^{19}F NMR. All chemical shifts for ^1H and ^{13}C NMR spectroscopy were assigned to residual signals from CDCl_3 (^1H) at 7.25 ppm and (^{13}C) at 77.13 ppm. High resolution mass spectra (HRMS) were obtained using a JEOL JMS-700 MStation mass spectrometer or obtained at Korea Basic Science Institute (Daegu, South Korea). Specific Optical rotations were obtained using a JASCO P-2000 Series Polarimeter (wavelength = 589 nm). Enantiomeric ratios were determined by chiral HPLC analysis using an Agilent 1260 infinity and Daicel Chiraldak (IC or ID) columns (4.6 mm x 25 cm). Absolute configuration of compound **6e** was determined by X-ray crystallography, and all other products are assigned by analogy.

List of abbreviations: TLC – Thin-layer chromatography, NMR – Nuclear magnetic resonance, IR - Infrared, HRMS – High resolution mass, THF – Tetrahydrofuran, DCM – Dichloromethane, EA – Ethyl acetate, DMF – *N,N*-Dimethylformamide , DMAP – 4-dimethylaminopyridine, IPA – isopropyl alcohol, EDC – 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, HOBr – Hydroxybenzotriazole, t_R – Retention time, ee – Enantiomeric excess.

2. Additional Screening Data and Unsuccessful Substrates^a




Entry	Solvent	ArB(OH) ₂	Additive (30 mol%)	Ligand	Yield [%] ^b	ee [%] ^c
1	H ₂ O	PhB(OH) ₂	NH ₄ PF ₆	(S)-t-BuPyOx	Trace	-
2	H ₂ O	PhB(OH) ₂	NH ₄ PF ₆	(S)-5-CF ₃ -t-BuPyOx	Trace	-
3	H ₂ O	PhB(OH) ₂	NH ₄ PF ₆	(S)-3c	97	95
4	H ₂ O/Toluene (1:1)	PhB(OH) ₂	NH ₄ PF ₆	(S)-3c	47	97
5	H ₂ O	PhB(OH) ₂	-	(S)-3c	42	90
5	Toluene	PhB(OH) ₂	-	(S)-3c	25	98
6	DMF	PhB(OH) ₂	-	(S)-3c	13	98
7	1,4-dioxane	PhB(OH) ₂	-	(S)-3c	Trace	-
8	n-BuOH	PhB(OH) ₂	-	(S)-3c	Complicated mixture ^d	-
9	DMSO	PhB(OH) ₂	-	(S)-3c	No reaction	-
10	H ₂ O	4-MePhB(OH) ₂	NH ₄ PF ₆	(S)-3c	71	96
11 ^e	H ₂ O	4-MePhB(OH) ₂	NH ₄ PF ₆	(S)-3c	77	96




^aUnless otherwise noted, all reactions were carried out with **4** (0.5 mmol, 1 equiv.), ArB(OH)₂ (0.6 mmol, 1.2 equiv.), Pd(TFA)₂ (0.025 mmol, 5 mol%), ligand (0.030 mmol, 6 mol%), additive (0.15 mmol, 30 mol%), H₂O (0.35 mL, 1.43 M) for 12 h. ^bIsolated yield. ^cDetermined by HPLC with DAICEL chiralpak. ^dNo desired product. ^eReaction carried out in H₂O (0.7 mL, 0.71 M).

Unsuccessful Substrates


Boronic Acid Substrates



2-Substituted Chromone Substrates



3. Ligand Synthesis




Compound **1a** and **1b** was prepared according to literature procedures.² To a flask charged with stir bar and CuI (2.26 mmol, 0.5 equiv.) in THF (9 mL, 0.5 M), aryl magnesium bromide (9.05 mmol, 2 equiv.) was slowly added at -78 °C and stirred for 15 min. **1a** or **1b** (4.52 mmol, 1.0 equiv.) was added to the mixture and the resulting suspension was warmed to 24 °C with vigorous stirring. Reaction was monitored by TLC (4:1 Hexanes/EtOAc), and stirred until starting material spot was disappeared. Then reaction was quenched with a saturated aqueous NH₄Cl solution (25 mL) and extracted with EtOAc (30 mL x3). The combined organic layers were dried over MgSO₄ and concentrated. Crude product was obtained as yellow solid. Filtered by short flash chromatography to remove dimer of Grignard reagent.

To a flask charged with glass-coated stir bar and Li (61.0 mmol, 16.0 equiv.) in THF (25 mL, 0.15 M), naphthalene (0.38 mmol, 0.10 equiv.) was added at 24 °C. When the color of solution changed to deep purple blue color, products (3.81 mmol, 1.0 equiv.) obtained from previous Grignard step were added to the suspension at -78 °C. The resulting suspension was warmed to 24 °C slowly and stirred for overnight. The solution was transferred through a cannula to another flask and quenched by saturated aqueous NH₄Cl solution (50 mL). After saturated aqueous NH₄Cl layer was discarded, 1M HCl aqueous solution was added to the solution and organic layer was discarded. Then 20% w/v NaOH aqueous solution was added to the acidic aqueous solution. When the pH of aqueous layer was 8, The aqueous layer was extracted with EtOAc and dried over MgSO₄. The residue was filtered and concentrated to afford chiral amines. The product used without further purification.

To a mixture of picolinic acid (2.15 mmol, 1.0 equiv.), chiral amine obtained from previous deprotection step (2.15 mmol, 1.0 equiv.), and HOBT (2.68 mmol, 1.25 equiv.) in DMF (2 mL, 0.35 M), EDC (2.68 mmol, 1.25 equiv.) was added at 0 °C and stirred for 12 h at 24 °C. The solution was quenched by water (10 mL), and extracted with EtOAc (15 mL) and dried over MgSO₄. The residue was filtered, concentrated and purified by flash chromatography. Compound **2a-2e** was obtained as pale yellow solid.


(S)-N-(4-methyl-1-phenylpentan-2-yl)picolinamide (2a)



Purified by column chromatography (4:1 Hexane/EtOAc), 66% overall yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.48 (d, J = 4.2 Hz, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 9.5 Hz, 1H), 7.76 (td, J = 7.7, 1.7 Hz, 1H), 7.34 (ddd, J = 7.5, 4.7, 1.2 Hz, 1H), 7.15-7.26 (m, 5H), 4.47 (qd, J = 10.0, 6.1 Hz, 1H), 2.88 (ddd, J = 29.6, 13.5, 6.3 Hz, 2H), 1.62-1.72 (m, 1H), 1.32-1.48 (m, 2H), 0.88 (d, J = 6.5 Hz, 6H); ¹³C-NMR (101 MHz, CDCl₃) δ 163.6, 149.9, 147.9, 138.1, 137.2, 129.5, 128.2, 126.2, 126.0, 122.1, 48.4, 43.2, 41.8, 24.9, 23.3, 21.9;

IR ν = 3661, 3376, 2958, 2909, 1673, 1519, 1466, 1433, 1384, 1251, 1161, 1077, 1055, 868, 819, 750, 701 cm⁻¹; HRMS (EI) calc'd for C₁₈H₂₂N₂O [M]⁺: 282.1732, found: 282.1730; [α]_D²⁵ -4.5 (c 1.06, CHCl₃);


(S)-N-(4-methyl-1-phenylpentan-2-yl)-5-(trifluoromethyl)picolinamide (2b)



Purified by column chromatography (8:1 Hexane/EtOAc), 63% overall yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.78 (s, 1H), 8.30 (d, J = 8.2 Hz, 1H), 8.07 (dd, J = 8.1, 2.2 Hz, 1H), 7.82 (d, J = 9.2 Hz, 1H), 7.17-7.28 (m, 5H), 4.43-4.53 (m, 1H), 2.90 (d, J = 6.4 Hz, 2H), 1.62-1.72 (m, 1H), 1.37-1.51 (m, 2H), 0.90 (dd, J = 6.5, 1.9 Hz, 6H); ¹³C-NMR (101 MHz, CDCl₃) δ 162.3, 153.0, 145.2 (q, J = 3.8 Hz), 137.9, 134.8 (q, J = 3.8 Hz), 129.6, 128.7 (q, J = 33.7 Hz), 128.4, 126.5, 123.3 (q, J = 274.5 Hz), 122.2, 48.8, 43.4, 41.7, 25.1, 23.4, 22.0; ¹⁹F-NMR (376 MHz, CDCl₃) δ -62.39;

IR ν = 3668, 3377, 2983, 2898, 1678, 1577, 1523, 1327, 1165, 1136, 1077, 1018, 941, 870, 753, 702 cm⁻¹; HRMS (EI) calc'd for C₁₉H₂₁F₃N₂O [M]⁺: 350.1606, found: 350.1608; [α]_D²⁵ -2.0 (c 0.55, CHCl₃)


(S)-N-(1-(2,6-dimethylphenyl)-3-phenylpropan-2-yl)-5-(trifluoromethyl)picolinamide (2c)



Purified by column chromatography (10:1 Hexane/EtOAc), 67% overall yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.78 (s, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.00-8.04 (m, 2H), 7.26-7.28 (m, 1H), 7.17-7.24 (m, 4H), 6.93-6.99 (m, 3H), 4.56-4.62 (m, 1H), 2.91-3.07 (m, 4H), 2.33 (s, 6H); ¹³C-NMR (101 MHz, CDCl₃) δ 162.3, 152.7, 145.1 (q, J = 3.9 Hz), 138.2, 136.9, 135.1, 134.8 (q, J = 2.8 Hz), 129.3, 128.7 (q, J = 33.7 Hz), 128.5, 128.5, 126.6, 126.4, 123.3 (q, J = 273.5 Hz), 122.01, 51.54, 41.19, 34.45, 20.50; ¹⁹F-NMR (376 MHz, CDCl₃) δ -62.32;

IR ν = 3673, 2985, 2911, 1605, 1562, 1470, 1391, 1321, 1162, 1128, 1078, 1016, 966, 858, 766 cm⁻¹; HRMS (EI) calc'd for C₂₄H₂₃F₃N₂O [M]⁺: 412.1762, found: 412.1764; [α]_D²⁵ +54.4 (c 1.31, CHCl₃)


(S)-N-(1-(2,6-diethylphenyl)-3-phenylpropan-2-yl)-5-(trifluoromethyl)picolinamide (2d)



Purified by column chromatography (8:1 Hexane/EtOAc), 55% overall yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.82 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 8.02 (dd, J = 8.2, 1.7 Hz, 1H), 7.30-7.34 (m, 4H), 7.21-7.26 (m, 1H), 7.15 (dd, J = 8.2, 6.7 Hz, 1H), 7.07 (d, J = 7.6 Hz, 2H), 4.66 (td, J = 14.9, 8.0 Hz, 1H), 3.00-3.23 (m, 4H), 2.78 (tt, J = 21.8, 7.3 Hz, 4H), 1.26 (t, J = 7.4 Hz, 6H); ¹³C-NMR (101 MHz, CDCl₃) δ 162.3, 152.7, 145.0 (q, J = 3.9 Hz), 143.0, 138.2, 134.6 (q, J = 2.9 Hz), 133.2, 129.2, 128.5 (q, J = 33.7 Hz), 128.4, 126.8, 126.5, 126.4, 123.2 (q, J = 274.4 Hz), 121.9, 52.6, 40.8, 32.8, 26.2, 15.7; ¹⁹F-NMR (376 MHz, CDCl₃) δ -62.29;


IR ν = 3385, 2963, 1681, 1579, 1520, 1455, 1327, 1166, 1136, 1076, 1018, 870, 756, 702 cm⁻¹; HRMS (EI) calc'd for C₂₆H₂₇F₃N₂O [M]⁺: 440.2075, found: 440.2078; [α]_D²⁵ +0.5 (c 1.55, CHCl₃)

(S)-N-(1-phenyl-3-(2,4,6-triisopropylphenyl)propan-2-yl)-5-(trifluoromethyl) picolinamide (2e)




Purified by column chromatography (8:1 Hexane/EtOAc), 47% overall yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.21-7.33 (m, 5H), 6.98 (s, 2H), 4.52 (td, J = 14.7, 7.2 Hz, 1H), 2.97-3.24 (m, 6H), 2.81-2.92 (m, 1H), 1.18-1.29 (m, 18H); ¹³C-NMR (101 MHz, CDCl₃) δ 162.5, 152.8, 147.4, 146.9, 145.0 (q, J = 3.8 Hz), 138.5, 134.7 (q, J = 2.9 Hz), 129.3, 128.9, 128.7 (q, J = 33.7 Hz), 128.5, 126.6, 123.3 (q, J = 273.5 Hz), 122.0, 121.1, 53.5, 40.9, 34.1, 31.6, 29.5, 24.5, 24.1, 24.0; ¹⁹F-NMR (376 MHz, CDCl₃) δ -62.30;

IR ν = 3407, 2960, 1678, 1606, 1575, 1510, 1473, 1326, 1165, 1141, 1076, 1018, 940, 872, 752, 705 cm⁻¹; HRMS (EI) calc'd for C₃₁H₃₇F₃N₂O [M]⁺: 510.2858, found: 510.2860; [α]_D²⁵ +1.83 (c=2.23, CHCl₃)



To a mixture of picolinamide **2a-2e** (1.04 mmol, 1.0 equiv.) and DMAP (3.13 mmol, 3.0 equiv.) in toluene (42 mL, 0.025 M), Tf_2O (5.22 mmol, 5.0 equiv.) was added dropwise. The mixture was heated to 90 °C in an oil bath and stirred for 12 h. The solution was cooled to 24 °C, quenched by Na_2CO_3 (50 mL), extracted with EtOAc (60 mL, x3) and dried over MgSO_4 successively. The residue was filtered, concentrated and purified by flash chromatography. Compound **2a-2e** was obtained as pale reddish brown oil (**3a**), or pale yellow solid (**3b**, **3c**, **3d**, **3e**).


(S)-3-isobutyl-1-(pyridin-2-yl)-3,4-dihydroisoquinoline (**3a**)



Purified by column chromatography (9:1 Hexane/EtOAc), 93% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.62 (d, $J = 4.2$ Hz, 1H), 7.85 (d, $J = 7.6$ Hz, 1H), 7.76 (td, $J = 7.6, 1.9$ Hz, 1H), 7.39 (d, $J = 7.6$ Hz, 1H), 7.28-7.35 (m, 2H), 7.19-7.25 (m, 2H), 3.66-3.73 (m, 1H), 2.81 (dd, $J = 15.4, 5.1$ Hz, 1H), 2.59 (dd, $J = 15.4, 12.0$ Hz, 1H), 1.98-2.08 (m, 1H), 1.77-1.84 (m, 1H), 1.44-1.50 (m, 1H), 0.97 (dd, $J = 6.7, 2.1$ Hz, 6H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 164.6, 157.3, 148.3, 138.4, 136.8, 130.6, 128.1, 128.1, 127.5, 126.5, 123.9, 123.7, 55.3, 44.7, 31.9, 24.8, 22.8, 22.7;

IR ν = 3671, 2953, 2909, 1609, 1562, 1466, 1433, 1325, 1243, 1050, 994, 967, 900, 802, 746, 719, 689, 667 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{18}\text{H}_{20}\text{N}_2$ [M] $^+$: 264.1626, found: 264.1625; $[\alpha]_D^{25} +136.6$ (c 0.95, CHCl_3);


(S)-3-isobutyl-1-(5-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroisoquinoline (**3b**)



Purified by column chromatography (13:1 Hexane/EtOAc), 89% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.91 (s, 1H), 8.04 (d, $J = 1.5$ Hz, 2H), 7.36-7.42 (m, 2H), 7.26 (t, $J = 8.0$ Hz, 2H), 3.73 (ddd, $J = 19.7, 7.0, 5.2$ Hz, 1H), 2.84 (dd, $J = 15.6, 5.0$ Hz, 1H), 2.61 (dd, $J = 15.4, 12.4$ Hz, 1H), 2.00-2.10 (m, 1H), 1.77-1.84 (m, 1H), 1.46-1.53 (m, 1H), 0.99 (q, $J = 3.3$ Hz, 6H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 163.7, 160.7, 145.4 (q, $J = 3.8$ Hz), 138.5, 134.1 (q, $J = 3.8$ Hz), 131.1, 127.9, 127.8, 127.8, 126.7, 126.6 (q, $J = 33.6$ Hz), 123.9, 123.6 (q, $J = 281.2$ Hz), 55.8, 44.8, 32.0, 24.9, 22.8, 22.8; $^{19}\text{F-NMR}$ (376 MHz, CDCl_3) δ -62.32;

IR ν = 3661, 2983, 2954, 1605, 1562, 1467, 1390, 1321, 1164, 1131, 1078, 1017, 967, 861, 746 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{19}\text{H}_{19}\text{F}_3\text{N}_2$ [M] $^+$: 332.1500, found: 332.1497; $[\alpha]_D^{25} +122.9$ (c 0.64, CHCl_3);


(S)-3-(2,6-dimethylbenzyl)-1-(5-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroisoquinoline (**3c**)



Purified by column chromatography (13:1 Hexane/EtOAc), 81% yield. Carefully rinsed three times with distilled petroleum ether at 0 °C. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.96 (s, 1H), 8.03-8.09 (m, 2H), 7.49 (d, $J = 7.8$ Hz, 1H), 7.40 (td, $J = 7.6, 1.2$ Hz, 1H), 7.29 (t, $J = 7.6$ Hz, 1H), 7.22-7.25 (m, 1H), 7.07-7.13 (m, 3H), 3.90-3.98 (m, 1H), 3.39 (q, $J = 6.7$ Hz, 1H), 3.11 (dd, $J = 13.7, 8.7$ Hz, 1H), 2.71-2.83 (m, 2H), 2.41 (s, 6H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 163.9, 160.4, 145.4 (q, $J = 3.8$ Hz), 138.4, 137.2, 136.3, 134.1 (q, $J = 3.8$ Hz), 131.2, 128.4, 128.0, 127.9, 127.6, 126.8, 126.6 (q, $J = 33.6$ Hz), 126.2, 123.8, 123.6 (q, $J = 273.4$ Hz), 58.2, 35.6, 31.2, 20.7; $^{19}\text{F-NMR}$ (376 MHz, CDCl_3) δ -62.32;

IR ν = 3678, 2983, 2917, 1605, 1562, 1470, 1391, 1321, 1162, 1128, 1078, 966, 858, 766 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{24}\text{H}_{21}\text{F}_3\text{N}_2$ [M] $^+$: 394.1657, found: 394.1656; $[\alpha]_D^{25}$ -75.5 (c 1.23, CHCl_3);


(S)-3-(2,6-diethylbenzyl)-1-(5-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroisoquinoline (3d)



Purified by column chromatography (13:1 Hexane/EtOAc), 56% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 9.01 (s, 1H), 8.10 (s, 2H), 7.56 (d, J = 7.6 Hz, 1H), 7.42 (t, J = 7.4 Hz, 1H), 7.17-7.34 (m, 5H), 3.91-3.99 (m, 1H), 3.47-3.54 (m, 1H), 3.20 (dd, J = 14.1, 8.8 Hz, 1H), 2.79-2.89 (m, 6H), 1.29 (t, J = 7.6 Hz, 6H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 163.7, 160.4, 145.3 (q, J = 4.7 Hz), 143.2, 138.4, 134.5, 133.9 (q, J = 2.8 Hz), 131.1, 128.0, 127.8, 127.6, 126.7, 126.6, 126.5 (q, J = 32.7 Hz), 126.3, 123.8, 123.5 (q, J = 273.5 Hz), 59.2, 34.1, 31.0, 26.3, 15.6; $^{19}\text{F-NMR}$ (376 MHz, CDCl_3) δ -62.15;


IR ν = 3597, 3065, 2961, 1605, 1562, 1456, 1391, 1320, 1163, 1129, 1078, 1016, 965, 854, 742 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{26}\text{H}_{25}\text{F}_3\text{N}_2$ [M] $^+$: 422.1970, found: 422.1968; $[\alpha]_D^{25}$ -1.4 (c 0.85, CHCl_3);

(S)-1-(5-(trifluoromethyl)pyridin-2-yl)-3-(2,4,6-triisopropylbenzyl)-3,4-dihydroisoquinoline (3e)




Purified by column chromatography (13:1 Hexane/EtOAc), 37% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.96 (s, 1H), 8.07 (s, 2H), 7.37-7.46 (m, 2H), 7.22-7.30 (m, 2H), 7.05 (s, 2H), 3.82-3.90 (m, 1H), 3.29-3.40 (m, 3H), 3.10 (dd, J = 14.1, 9.2 Hz, 1H), 2.72-2.95 (m, 3H), 1.19-1.30 (m, 18H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 163.9, 160.6, 147.7, 146.9, 145.5 (q, J = 3.9 Hz), 138.4, 134.0 (q, J = 2.9 Hz), 131.2, 130.1, 128.0, 127.7, 126.8 (q, J = 32.7 Hz), 126.8, 124.0, 123.6 (q, J = 273.5 Hz), 121.1, 59.8, 34.2, 32.9, 30.5, 29.5, 24.8, 24.3, 24.2; $^{19}\text{F-NMR}$ (376 MHz, CDCl_3) δ -62.23;

IR ν = 3678, 2983, 2901, 1606, 1563, 1459, 1389, 1321, 1164, 1132, 1078, 1016, 966, 938, 860 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{31}\text{H}_{35}\text{F}_3\text{N}_2$ [M] $^+$: 492.2752, found: 492.2750; $[\alpha]_D^{25}$ -0.9 (c 0.71, CHCl_3);



To a solution of **(S)-3d** (0.15 mmol, 1.0 equiv.) in toluene (1.5 mL, 0.1 M), PdCl_2 (0.15 mmol, 1.0 equiv.) was added. The mixture was stirred and refluxed for 24 h. The mixture was cooled to 24 °C, filtered, concentrated and purified with flash chromatography. Compound **[(S)-3d]PdCl₂** was obtained as yellow solid.


((S)-3-(2,6-diethylbenzyl)-1-(5-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroisoquinoline) chloride ([*(S*)-3d]PdCl₂) palladium(II)



Purified by column chromatography (15:1 Hexane/EtOAc), 43% yield. ¹H-NMR (400 MHz, CDCl_3) δ 8.93 (s, 1H), 8.01-8.06 (m, 2H), 7.45 (d, J = 7.6 Hz, 1H), 7.37 (t, J = 7.1 Hz, 1H), 7.27 (d, J = 7.6 Hz, 1H), 7.17-7.20 (m, 2H), 7.10 (d, J = 7.6 Hz, 2H), 3.81-3.89 (m, 1H), 3.40 (dd, J = 13.7, 6.1 Hz, 1H), 3.10 (dd, J = 13.9, 9.0 Hz, 1H), 2.67-2.81 (m, 6H), 1.20 (t, J = 7.4 Hz, 6H); ¹³C-NMR (101 MHz, CDCl_3) δ 170.3, 159.2, 148.9 (q, J = 3.8 Hz), 143.9, 137.5, 137.2 (q, J = 2.8 Hz), 134.5, 132.1, 130.5 (q, J = 34.7 Hz), 130.2, 128.5, 127.6 (q, 2.9 Hz), 127.1, 126.5, 125.9, 123.2, 120.5, 57.0, 29.9, 29.0, 26.3, 16.0; ¹⁹F-NMR (376 MHz, CDCl_3) δ -62.57


Elemental Analysis Calc'd for $\text{C}_{26}\text{H}_{25}\text{Cl}_2\text{F}_3\text{N}_2\text{Pd}$ (%): C 52.06, H 4.20, N 4.67; found C 52.44, H 4.77, N 4.47; $[\alpha]_D^{25} +0.01$ (c 0.22, CHCl_3);

4. Experimental Procedures




H_2O (700 μL , 0.71 M) was added through 500 μL glass microsyringes to a 4 mL screw-top septum vial charged with a stir bar, chromones (0.50 mmol), $\text{Pd}(\text{OCOCF}_3)_2$ (8.30 mg, 0.025 mmol), **(S)-3c** (11.8 mg, 0.03 mmol), NH_4PF_6 (24.4 mg, 0.15 mmol) and arylboronic acid (0.60 mmol). O_2 balloon was equipped to the septum of the vial. The mixture was heated to 70 °C and stirred for 20 h. The reaction was monitored by TLC (4:1 hexanes/EtOAc). To the reaction vial, EA (300 μL , x3) was added to extract products. After brief extraction, the organic layer (EA) was directly loaded on the silica gel and purified by column chromatography in each condition to afford desired products. Absolute configuration of compound **6e** was determined by X-ray crystallography, and all other products are assigned by analogy.

(S)-2-methyl-2-phenylchroman-4-one (6a)




Purified by column chromatography (11:1 Hexane/EtOAc), 98% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.76 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.39-7.48 (m, 3H), 7.32-7.17 (3H), 7.06 (dd, $J = 8.4, 0.8$ Hz, 1H), 6.90-6.94 (m, 1H), 3.31 (d, $J = 16.4$ Hz, 1H), 3.08 (d, $J = 16.4$ Hz, 1H), 1.75 (s, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 191.8, 160.1, 143.0, 136.3, 128.7, 127.7, 126.7, 125.3, 121.1, 121.0, 118.4, 82.5, 48.1, 30.0; The data matched with previously reported literature.³

IR ν = 2997, 2896, 2361, 1692, 1607, 1461, 1376, 1312, 1272, 1236, 1177, 1121, 1051, 952, 890, 765, 701 cm^{-1} ; $[\alpha]_D^{25} +12.1$ (c 0.54, CHCl_3); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiraldak IC column, $\lambda = 220$ nm, t_R (min): major = 6.1, minor = 7.55, 95% ee.




(S)-2-methyl-2-(*p*-tolyl)chroman-4-one (6b)




Purified by column chromatography (13:1 Hexane/EtOAc), 80% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.75 (dd, J = 7.8, 1.6 Hz, 1H), 7.43-7.47 (m, 1H), 7.29 (dt, J = 8.4, 1.9 Hz, 2H), 7.03-7.10 (m, 3H), 6.89-6.93 (m, 1H), 3.29 (d, J = 16.5 Hz, 1H), 3.06 (d, J = 16.5 Hz, 1H), 2.27 (s, 3H), 1.74 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.9, 160.2, 140.0, 137.5, 136.2, 129.4, 126.7, 125.3, 121.2, 121.1, 118.4, 82.5, 48.2, 30.2, 21.1; The data matched with previously reported literature.³

IR ν = 3673, 2955, 1693, 1607, 1461, 1375, 1311, 1273, 1237, 1175, 1120, 1050, 951, 890, 818, 766 cm⁻¹; [α]_D²⁵ +38.5 (c 0.77, CHCl₃); HPLC Conditions: 3% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak ID column, λ = 220 nm, t_R (min): major = 7.72, minor = 8.20, 96% ee.




(S)-2-(4-ethylphenyl)-2-methylchroman-4-one (6c)




Purified by column chromatography (13:1 Hexane/EtOAc), 85% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.75 (dd, J = 7.8, 1.7 Hz, 1H), 7.43-7.47 (m, 1H), 7.31 (dt, J = 8.4, 2.1 Hz, 2H), 7.11 (d, J = 8.4 Hz, 2H), 7.05 (dd, J = 8.4, 0.8 Hz, 1H), 6.90-6.94 (m, 1H), 3.30 (d, J = 16.4 Hz, 1H), 3.06 (d, J = 16.4 Hz, 1H), 2.57 (q, J = 7.6 Hz, 2H), 1.74 (s, 3H), 1.18 (t, J = 7.4 Hz, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 192.0, 160.2, 143.7, 140.2, 136.2, 128.2, 126.7, 125.3, 121.2, 121.0, 118.4, 82.5, 48.2, 30.1, 28.4, 15.3;

IR ν = 2968, 2929, 1692, 1607, 1514, 1461, 1415, 1375, 1309, 1273, 1236, 1175, 1121, 1078, 1044, 951, 890, 832, 765 cm⁻¹; HRMS (EI) calc'd for C₁₈H₁₈O₂ [M]⁺: 266.1307, found: 266.1294; [α]_D²⁵ +33.8 (c 0.89, CHCl₃); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak IC column, λ = 220 nm, t_R (min): major = 5.86, minor = 7.78, 98% ee.




(S)-2-(4-methoxyphenyl)-2-methylchroman-4-one (6d)




Purified by column chromatography (9:1 Hexane/EtOAc), 51% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.75 (dd, J = 7.8, 1.8 Hz, 1H), 7.42-7.46 (m, 1H), 7.30-7.34 (m, 2H), 7.02 (d, J = 8.2 Hz, 1H), 6.89-6.93 (m, 1H), 6.78-6.82 (m, 2H), 3.73 (s, 3H), 3.28 (d, J = 16.5 Hz, 1H), 3.05 (d, J = 16.5 Hz, 1H), 1.73 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 192.0, 160.1, 159.0, 136.2, 134.9, 126.7, 121.2, 121.0, 118.4, 114.0, 82.4, 55.3, 48.1, 30.3; The data matched with previously reported literature.³

IR ν = 2976, 2367, 1691, 1609, 1513, 1461, 1415, 1376, 1310, 1252, 1182, 1122, 1079, 1033, 950, 890, 832, 768 cm⁻¹; [α]_D²⁵ +42.5 (c 0.37, CHCl₃); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak IC column, λ = 220 nm, t_R (min): major = 8.41, minor = 11.24, 90% ee.




(S)-2-(4-(tert-butyl)phenyl)-2-methylchroman-4-one (6e)




Purified by column chromatography (15:1 Hexane/EtOAc), 78% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.76 (dd, $J = 7.8, 1.8$ Hz, 1H), 7.44-7.48 (m, 1H), 7.28-7.34 (m, 4H), 7.05 (dd, $J = 8.2, 0.7$ Hz, 1H), 6.90-6.94 (m, 1H), 3.30 (d, $J = 16.5$ Hz, 1H), 3.05 (d, $J = 16.5$ Hz, 1H), 1.74 (s, 3H), 1.26 (s, 9H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 192.0, 160.2, 150.6, 140.0, 136.2, 126.7, 125.6, 125.0, 121.1, 121.0, 118.5, 82.5, 48.2, 34.5, 31.3, 29.9;

IR ν = 2962, 2360, 1693, 1608, 1510, 1462, 1401, 1363, 1310, 1273, 1239, 1120, 1082, 1016, 952, 891, 835, 763 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{20}\text{H}_{22}\text{O}_2$ [M] $^+$: 294.1620, found: 294.1610; $[\alpha]_D^{25} +27.5$ (c 0.95, CHCl_3); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak IC column, $\lambda = 220$ nm, t_R (min): major = 5.12, minor = 6.89, 98% ee.




(S)-2-(3-methoxyphenyl)-2-methylchroman-4-one (6f)




Purified by column chromatography (9:1 Hexane/EtOAc), 81% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.75 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.43-7.48 (m, 1H), 7.20 (t, $J = 8.2$ Hz, 1H), 7.05 (d, $J = 8.4$ Hz, 1H), 6.91-6.97 (m, 3H), 6.73-6.76 (m, 1H), 3.74 (s, 3H), 3.28 (d, $J = 16.8$ Hz, 1H), 3.07 (d, $J = 16.4$ Hz, 1H), 1.74 (s, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 191.7, 160.1, 159.9, 144.8, 136.3, 129.8, 126.7, 121.2, 118.4, 117.7, 112.8, 111.6, 82.5, 55.3, 48.2, 30.0; The data matched with previously reported literature.³

IR ν = 3072, 2836, 1691, 1607, 1461, 1376, 1325, 1290, 1237, 1177, 1150, 1121, 1046, 952, 868, 767, 701 cm^{-1} ; $[\alpha]_D^{25} +34.0$ (c 1.00, CHCl_3); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak IC column, $\lambda = 220$ nm, t_R (min): major = 8.30, minor = 12.01, 99% ee.




(S)-2-methyl-2-(*m*-tolyl)chroman-4-one (6g)




Purified by column chromatography (15:1 Hexane/EtOAc), 82% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.76 (dd, J = 7.8, 1.7 Hz, 1H), 7.44-7.48 (m, 1H), 7.15-7.21 (m, 3H), 7.02-7.07 (m, 2H), 6.92 (td, J = 7.4, 1.0 Hz, 1H), 3.29 (d, J = 16.4 Hz, 1H), 3.06 (d, J = 16.8 Hz, 1H), 2.30 (s, 3H), 1.73 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.9, 160.2, 143.1, 138.3, 136.2, 128.6, 128.6, 126.7, 126.0, 122.4, 121.1, 121.1, 118.5, 82.5, 48.2, 29.9, 21.7; The data matched with previously reported literature.³

IR ν = 2978, 2922, 2361, 1692, 1607, 1461, 1376, 1325, 1278, 1237, 1120, 1081, 1044, 952, 896, 865, 766, 704cm⁻¹; [α]_D²⁵+10.4 (c 0.91, CHCl₃); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiraldpak IC column, λ = 220 nm, t_R (min): major = 6.12, minor = 7.01, 99% ee.




(S)-2-(3,5-dimethylphenyl)-2-methylchroman-4-one (6h)




Purified by column chromatography (15:1 Hexane/EtOAc), 77% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.76 (dd, J = 8.0, 1.6 Hz, 1H), 7.43-7.48 (m, 1H), 7.06 (dd, J = 8.2, 0.9 Hz, 1H), 7.02 (s, 2H), 6.90-6.94 (m, 1H), 6.85 (s, 1H), 3.29 (d, J = 16.5 Hz, 1H), 3.04 (d, J = 16.5 Hz, 1H), 2.26 (s, 6H), 1.72 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.9, 160.2, 143.1, 138.2, 136.2, 129.4, 126.7, 123.1, 121.1, 121.0, 118.4, 82.5, 48.2, 29.8, 21.5; The data matched with previously reported literature.³

IR ν = 2977, 2920, 1693, 1608, 1461, 1376, 1303, 1238, 1181, 1122, 1081, 1045, 939, 899, 851, 765, 706 cm⁻¹; [α]_D²⁵ +8.4 (c 1.00, CHCl₃); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak IC column, λ = 220 nm, t_R (min): major = 5.51, minor = 6.63, 97% ee.




(S)-2-(benzo[d][1,3]dioxol-5-yl)-2-methylchroman-4-one (6i)




Purified by column chromatography (13:1 Hexane/EtOAc), 47% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.75 (dd, J = 7.8, 1.7 Hz, 1H), 7.42-7.46 (m, 1H), 7.01 (dd, J = 8.4, 0.8 Hz, 1H), 6.89-6.93 (m, 2H), 6.81 (dd, J = 8.4, 1.9 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 5.87 (dd, J = 4.6, 1.5 Hz, 2H), 3.24 (d, J = 16.4 Hz, 1H), 3.04 (d, J = 16.8 Hz, 1H), 1.71 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.7, 159.9, 148.1, 147.1, 136.9, 136.2, 126.6, 121.2, 118.9, 118.4, 108.1, 106.2, 101.2, 82.4, 48.1, 30.4; The data matched with previously reported literature.³

IR ν = 2978, 2900, 2373, 1689, 1608, 1488, 1461, 1325, 1236, 1119, 1039, 935, 881, 812, 768 cm⁻¹; [α]_D²⁵ +67.2 (c 0.50, CHCl₃); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak IC column, λ = 220 nm, t_R (min): major = 9.65, minor = 13.66, 96% ee.




(S)-2-(4-fluorophenyl)-2-methylchroman-4-one (6j)




Purified by column chromatography (15:1 Hexane/EtOAc), 80% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.75 (dd, J = 7.8, 1.8 Hz, 1H), 7.46 (ddd, J = 8.6, 6.9, 1.5 Hz, 1H), 7.35-7.40 (m, 2H), 7.03 (dd, J = 8.2, 0.7 Hz, 1H), 6.91-6.99 (m, 3H), 3.27 (d, J = 16.5 Hz, 1H), 3.07 (d, J = 16.5 Hz, 1H), 1.73 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.6, 162.2 (d, J = 248.4 Hz), 159.9, 138.9 (d, J = 2.9 Hz), 136.4, 127.2 (d, J = 8.7 Hz), 126.7, 121.3, 121.1, 118.4, 115.6 (d, J = 21.2 Hz), 82.2, 48.2, 30.2; ¹⁹F-NMR (376 MHz, CDCl₃) δ -114.50; The data matched with previously reported literature.³

IR ν = 3665, 2963, 1691, 1606, 1461, 1416, 1308, 1271, 1233, 1163, 1121, 1051, 1015, 952, 892, 837, 767 cm⁻¹; [α]_D²⁵ +15.4 (c 0.93, CHCl₃); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak IC column, λ = 220 nm, t_R (min): major = 6.25, minor = 7.27, 98% ee.




(S)-2-(4-chlorophenyl)-2-methylchroman-4-one (6k)




Purified by column chromatography (15:1 Hexane/EtOAc), 86% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.75 (dd, J = 7.8, 1.6 Hz, 1H), 7.44-7.48 (m, 1H), 7.34 (dt, J = 9.1, 2.4 Hz, 2H), 7.23-7.27 (m, 2H), 7.04 (dd, J = 8.5, 0.7 Hz, 1H), 6.92-6.96 (m, 1H), 3.25 (d, J = 16.5 Hz, 1H), 3.07 (d, J = 16.5 Hz, 1H), 1.73 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.4, 159.8, 141.7, 136.4, 133.7, 128.9, 126.8, 126.8, 121.4, 121.1, 118.4, 82.2, 48.0, 30.1; The data matched with previously reported literature.³

IR ν = 3671, 2959, 1693, 1607, 1461, 1400, 1308, 1270, 1236, 1175, 1121, 1096, 1013, 953, 891, 829, 765, 740 cm⁻¹; [α]_D²⁵ +22.7 (c 0.94, CHCl₃); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak IC column, λ = 220 nm, t_R (min): major = 6.31, minor = 7.81, 99% ee.




(S)-2-(4-bromophenyl)-2-methylchroman-4-one (6l)




Purified by column chromatography (15:1 Hexane/EtOAc), 80% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.74 (dd, J = 7.8, 1.7 Hz, 1H), 7.39-7.48 (m, 3H), 7.25-7.29 (m, 2H), 7.04 (dd, J = 8.4, 0.8 Hz, 1H), 6.94 (td, J = 7.5, 1.0 Hz, 1H), 3.25 (d, J = 16.4 Hz, 1H), 3.07 (d, J = 16.4 Hz, 1H), 1.72 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.4, 159.8, 142.2, 136.4, 131.9, 127.2, 126.8, 121.9, 121.4, 121.1, 118.4, 82.2, 48.0, 30.0; The data matched with previously reported literature.³

IR ν = 2984, 2903, 1693, 1607, 1461, 1309, 1271, 1235, 1121, 1080, 1009, 953, 891, 825, 770 cm⁻¹; [α]_D²⁵ +19.1 (c 0.40, CHCl₃); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak IC column, λ = 220 nm, t_R (min): major = 6.51, minor = 8.04, 98% ee.




(S)-2-methyl-2-(4-(trifluoromethyl)phenyl)chroman-4-one (6m)




Purified by column chromatography (13:1 Hexane/EtOAc), 31% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.76 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.46-7.57 (m, 5H), 7.07 (d, $J = 9.2$ Hz, 1H), 6.94-6.98 (m, 1H), 3.29 (d, $J = 16.4$ Hz, 1H), 3.12 (d, $J = 16.4$ Hz, 1H), 1.75 (s, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 191.2, 159.8, 147.2, 136.6, 130.1 (q, $J = 32.7$ Hz) 126.8, 125.8 (q, $J = 3.8$ Hz), 124.0 (q, $J = 273.5$ Hz), 121.6, 121.1, 118.4, 82.2, 48.0, 29.9; $^{19}\text{F-NMR}$ (376 MHz, CDCl_3) δ -62.55; The data matched with previously reported literature.³

IR $\nu = 3669, 2963, 1693, 1607, 1462, 1410, 1326, 1236, 1168, 1122, 1080, 1016, 954, 893, 844, 766 \text{ cm}^{-1}$; $[\alpha]_D^{25} = 8.3$ (c 0.36, CHCl_3); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiraldak IC column, $\lambda = 220$ nm, t_R (min): major = 5.24, minor = 6.52, 99% ee.




(S)-2-(3-fluorophenyl)-2-methylchroman-4-one (6n)




Purified by column chromatography (16:1 Hexane/EtOAc), 60% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.76 (dd, J = 7.8, 1.7 Hz, 1H), 7.46-7.50 (m, 1H), 7.23-7.29 (m, 1H), 7.12-7.16 (m, 2H), 7.06 (dd, J = 8.4, 0.8 Hz, 1H), 6.89-6.97 (m, 2H), 3.25 (d, J = 16.8 Hz, 1H), 3.08 (d, J = 16.4 Hz, 1H), 1.73 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.4, 163.1 (d, J = 247.5 Hz), 159.8, 146.0 (d, J = 6.8 Hz), 136.5, 130.4 (d, J = 8.7 Hz), 126.8, 121.4, 121.1, 120.9 (d, J = 2.9 Hz), 118.4, 114.9 (d, J = 21.2 Hz), 112.7 (d, J = 23.1 Hz), 82.1, 48.1, 29.9; ¹⁹F-NMR (376 MHz, CDCl₃) δ -111.81;

IR ν = 2971, 1692, 1609, 1461, 1377, 1326, 1274, 1235, 1121, 1045, 954, 910, 879, 766, 700 cm⁻¹; HRMS (EI) calc'd for C₁₆H₁₃FO₂ [M]⁺: 256.0900, found: 256.0894; [α]_D²⁵ -3.5 (c 0.46, CHCl₃); HPLC Conditions: 8% IPA/Hexanes, 0.9 mL/min, Daicel Chiralpak ID column, λ = 220 nm, t_R (min): major = 7.23, minor = 7.59, 96% ee.




(S)-2-(3-chlorophenyl)-2-methylchroman-4-one (6o)




Purified by column chromatography (16:1 Hexane/EtOAc), 55% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.76 (dd, J = 7.9, 1.7 Hz, 1H), 7.46-7.50 (m, 1H), 7.42 (t, J = 1.8 Hz, 1H), 7.18-7.28 (m, 3H), 7.06 (dd, J = 8.4, 0.6 Hz, 1H), 6.93-6.97 (m, 1H), 3.24 (d, J = 16.5 Hz, 1H), 3.07 (d, J = 16.5 Hz, 1H), 1.73 (s, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.2, 159.8, 145.4, 136.5, 134.9, 130.0, 128.1, 126.8, 125.7, 123.4, 121.4, 121.0, 118.5, 82.1, 48.1, 29.7; The data matched with previously reported literature.³

IR ν = 3675, 2977, 1692, 1607, 1461, 1418, 1377, 1325, 1235, 1165, 1122, 1079, 1047, 954, 893, 765, 698 cm⁻¹; [α]_D²⁵ +8.6 (c 0.89, CHCl₃); HPLC Conditions: 1% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak ID column, λ = 220 nm, t_R (min): major = 10.08, minor = 10.57, 92% ee.




(S)-2-ethyl-2-phenylchroman-4-one (8a)




Purified by column chromatography (15:1 Hexane/EtOAc), 93% yield. ¹H-NMR (400 MHz, CDCl₃) δ 7.73 (dd, J = 8.0, 1.5 Hz, 1H), 7.43-7.47 (m, 1H), 7.33-7.36 (m, 2H), 7.25-7.30 (m, 2H), 7.17-7.21 (m, 1H), 7.07 (dd, J = 8.4, 0.8 Hz, 1H), 6.88-6.92 (m, 1H), 3.26 (d, J = 16.4 Hz, 1H), 3.10 (d, J = 16.4 Hz, 1H), 1.97-2.13 (m, 2H), 0.85 (t, J = 7.4 Hz, 3H); ¹³C-NMR (101 MHz, CDCl₃) δ 191.9, 160.1, 141.3, 136.2, 128.5, 127.6, 126.6, 126.0, 121.4, 121.0, 118.4, 85.2, 46.2, 35.3, 8.0; The data matched with previously reported literature.³

IR ν = 2971, 1692, 1608, 1461, 1306, 1232, 1121, 1153, 1121, 1079, 1028, 957, 887, 760, 701 cm⁻¹; [α]_D²⁵ +7.0 (c 1.01, CHCl₃); HPLC Conditions: 5% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak ID column, λ = 220 nm, t_R (min): major = 6.75, minor = 7.25, 98% ee.




(R)-2-isopropyl-2-phenylchroman-4-one (8b)




Purified by column chromatography (15:1 Hexane/EtOAc), 47% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.66 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.39-7.44 (m, 1H), 7.14-7.30 (m, 5H), 7.04 (dd, $J = 8.4, 1.1$ Hz, 1H), 6.83-6.87 (m, 1H), 3.28 (d, $J = 16.4$ Hz, 1H), 3.14 (d, $J = 16.4$ Hz, 1H), 2.21-2.31 (m, 1H), 1.04 (d, $J = 6.9$ Hz, 3H), 0.86 (d, $J = 6.9$ Hz, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 192.4, 160.3, 140.0, 136.1, 128.2, 127.7, 127.1, 126.5, 121.6, 120.9, 118.4, 87.6, 42.4, 39.0, 17.5, 17.0; The data matched with previously reported literature.³

IR ν = 2975, 1692, 1608, 1461, 1306, 1233, 1118, 1030, 980, 898, 841, 760, 703 cm^{-1} ; $[\alpha]_D^{25}$ +71.1 (c 0.42, CHCl_3); HPLC Conditions: 5% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak ID column, $\lambda = 220$ nm, t_R (min): major = 6.38, minor = 6.70, 97% ee.




(R)-2-cyclohexyl-2-phenylchroman-4-one (8c)




Purified by column chromatography (15:1 Hexane/EtOAc), 48% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.65 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.39-7.43 (m, 1H), 7.13-7.29 (m, 5H), 7.03 (dd, $J = 8.4, 0.8$ Hz, 1H), 6.82-6.86 (m, 1H), 3.28 (d, $J = 16.4$ Hz, 1H), 3.16 (d, $J = 16.4$ Hz, 1H), 0.89-1.98 (m, 12H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 192.5, 160.3, 140.3, 136.0, 128.2, 127.6, 127.1, 126.5, 121.6, 120.8, 118.3, 87.5, 49.1, 42.9, 27.6, 27.0, 26.5, 26.4; The data matched with previously reported literature.³

IR ν = 3665, 2972, 2928, 1692, 1609, 1461, 1407, 1307, 1228, 1056, 902, 879, 842, 819, 760, 705 cm^{-1} ; $[\alpha]_D^{25}$ +43.5 (c 0.53, CHCl_3); HPLC Conditions: 1% MeOH/ Hexanes, 0.9 mL/min, Daicel Chiralpak ID column, $\lambda = 220$ nm, t_R (min): major = 6.08, minor = 6.41, 98% ee.




(S)-2-benzyl-2-phenylchroman-4-one (8d)




Purified by column chromatography (13:1 Hexane/EtOAc), 52% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.68 (dd, $J = 7.6, 1.5$ Hz, 1H), 7.45 (ddd, $J = 8.8, 6.9, 1.5$ Hz, 1H), 7.17-7.28 (m, 8H), 7.09 (dd, $J = 8.4, 0.8$ Hz, 1H), 6.97-7.02 (m, 2H), 6.89 (td, $J = 7.5, 0.9$ Hz, 1H), 3.36 (d, $J = 13.7$ Hz, 1H), 3.24 (d, $J = 16.4$ Hz, 1H), 3.17 (d, $J = 13.7$ Hz, 1H), 3.08 (d, $J = 16.4$ Hz, 1H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 191.8, 160.0, 141.2, 136.2, 135.3, 130.9, 128.5, 128.1, 127.9, 127.0, 126.6, 126.3, 121.5, 121.2, 118.5, 84.9, 49.7, 45.3;

IR $\nu = 3061, 3031, 2922, 2851, 1692, 1605, 1462, 1307, 1231, 1122, 1031, 996, 911, 768, 701 \text{ cm}^{-1}$; HRMS (FAB) calc'd for $\text{C}_{22}\text{H}_{18}\text{O}_2$ [$\text{M}+1$] $^+$: 315.1380, found: 315.1397; $[\alpha]_D^{25} +36.5$ (c 0.20, CHCl_3); HPLC Conditions: 3% MeOH/ Hexanes, 1.0 mL/min, Daicel Chiraldak ID column, $\lambda = 220$ nm, t_R (min): major = 6.82, minor = 6.36, 98% ee.




(S)-2,6-dimethyl-2-phenylchroman-4-one (8e)




Purified by column chromatography (13:1 Hexane/EtOAc), 89% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.54 (d, $J = 1.9$ Hz, 1H), 7.39-7.42 (m, 2H), 7.25-7.30 (m, 3H), 7.18-7.22 (m, 1H), 6.96 (d, $J = 8.4$ Hz, 1H), 3.29 (d, $J = 16.8$ Hz, 1H), 3.06 (d, $J = 16.4$ Hz, 1H), 2.22 (s, 3H), 1.73 (s, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 192.0, 158.1, 143.1, 137.3, 130.5, 128.6, 127.7, 126.3, 125.3, 120.7, 118.2, 82.3, 48.1, 30.1, 20.4;

IR ν = 3663, 2975, 1689, 1618, 1488, 1423, 1292, 1236, 1193, 1132, 953, 825, 762, 701 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{17}\text{H}_{16}\text{O}_2$ [$\text{M}+1$] $^+$: 252.1150, found: 252.1150; $[\alpha]_D^{25} +24.8$ (c 0.99, CHCl_3); HPLC Conditions: 10% IPA/ Hexanes, 1.0 mL/min, Daicel Chiraldak IC column, $\lambda = 220$ nm, t_R (min): major = 6.29, minor = 6.87, 98% ee.




(S)-6-methoxy-2-methyl-2-phenylchroman-4-one (8f)




Purified by column chromatography (10:1 Hexane/EtOAc), 88% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.37-7.40 (m, 2H), 7.17-7.30 (m, 4H), 7.06 (dd, $J = 9.0, 3.2$ Hz, 1H), 6.98 (d, $J = 9.2$ Hz, 1H), 3.71 (s, 3H), 3.30 (d, $J = 16.4$ Hz, 1H), 3.07 (d, $J = 16.4$ Hz, 1H), 1.73 (s, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 191.8, 154.7, 153.8, 143.1, 128.6, 127.7, 125.4, 125.3, 120.9, 119.7, 107.1, 82.4, 55.7, 47.9, 30.2; The data matched with previously reported literature.³

IR ν = 3669, 2965, 1688, 1619, 1487, 1431, 1284, 1220, 1174, 1123, 1072, 1032, 955, 878, 829, 766, 01 cm^{-1} ; $[\alpha]_D^{25} +39.5$ (c 1.09, CHCl_3); HPLC Conditions: 5% IPA/ Hexanes, 1.0 mL/min, Daicel Chiraldak IC column, $\lambda = 220$ nm, t_R (min): major = 10.75, minor = 10.14, 98% ee.




(S)-7-methoxy-2-methyl-2-phenylchroman-4-one (8g)




Purified by column chromatography (10:1 Hexane/EtOAc), 92% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.69 (d, $J = 8.8$ Hz, 1H), 7.40 (dt, $J = 7.9, 1.9$ Hz, 2H), 7.25-7.30 (m, 2H), 7.18-7.23 (m, 1H), 6.52-6.45 (2H), 3.81 (s, 3H), 3.24 (d, $J = 16.8$ Hz, 1H), 3.02 (d, $J = 16.8$ Hz, 1H), 1.73 (s, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 190.3, 166.3, 162.0, 143.2, 128.6, 128.4, 127.7, 125.1, 115.0, 109.4, 101.5, 82.9, 55.6, 47.8, 29.9;

IR ν = 3676, 2977, 2896, 1681, 1607, 1495, 1439, 1311, 1264, 1204, 1159, 1136, 1020, 980, 943, 839, 762, 702 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{17}\text{H}_{16}\text{O}_3$ [M] $^+$: 268.1099, found: 268.1094; $[\alpha]_D^{25}$ -95.4 (c 0.99, CHCl_3); HPLC Conditions: 5% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak ID column, $\lambda = 220$ nm, t_R (min): major = 14.95, minor = 16.86, 98% ee.




(S)-6-fluoro-2-methyl-2-phenylchroman-4-one (8h)




Purified by column chromatography (13:1 Hexane/EtOAc), 74% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.36-7.41 (m, 3H), 7.14-7.31 (m, 4H), 7.02 (q, $J = 4.5$ Hz, 1H), 3.32 (d, $J = 16.8$ Hz, 1H), 3.07 (d, $J = 16.4$ Hz, 1H), 1.74 (s, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 191.0, 157.0 (d, $J = 243.7$ Hz), 156.3 (d, $J = 1.9$ Hz), 142.6, 128.8, 127.9, 125.3, 123.7 (d, $J = 24.0$ Hz), 121.5 (d, $J = 6.8$ Hz), 120.0 (d, $J = 7.8$ Hz), 111.8 (d, $J = 23.1$ Hz), 82.8, 47.7, 30.1; $^{19}\text{F-NMR}$ (376 MHz, CDCl_3) δ -121.77;

IR ν = 2982, 2901, 1694, 1620, 1481, 1436, 1378, 1309, 1266, 1170, 1117, 1067, 955, 879, 828, 765, 701 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{16}\text{H}_{13}\text{FO}_2$ [M] $^+$: 256.0900, found: 256.0901; $[\alpha]_D^{25} +14.5$ (c 1.00, CHCl_3); HPLC Conditions: 5% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak ID column, $\lambda = 220$ nm, t_R (min): major = 6.51, minor = 6.89, 98% ee.




(S)-6-chloro-2-methyl-2-phenylchroman-4-one (8i)




Purified by column chromatography (13:1 Hexane/EtOAc), 90% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.70 (d, $J = 2.7$ Hz, 1H), 7.35-7.39 (m, 3H), 7.20-7.31 (m, 3H), 7.01 (d, $J = 8.8$ Hz, 1H), 3.32 (d, $J = 16.8$ Hz, 1H), 3.07 (d, $J = 16.4$ Hz, 1H), 1.75 (s, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 190.6, 158.5, 142.5, 136.0, 128.8, 128.0, 126.6, 126.1, 125.3, 121.9, 120.2, 83.0, 47.7, 30.1;

IR ν = 3675, 2976, 2901, 1696, 1603, 1469, 1422, 1267, 1229, 1177, 1131, 1068, 954, 897, 826, 763, 701 cm^{-1} ; HRMS (EI) calc'd for $\text{C}_{16}\text{H}_{13}\text{ClO}_2$ [M] $^+$: 272.0604, found: 272.0604; $[\alpha]_D^{25} +37.7$ (c 0.93, CHCl_3); HPLC Conditions: 5% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak ID column, $\lambda = 220$ nm, t_R (min): major = 6.48, minor = 7.01, 96% ee.




(S)-6-bromo-2-methyl-2-phenylchroman-4-one (8j)



Purified by column chromatography (13:1 Hexane/EtOAc), 64% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.85 (d, $J = 2.7$ Hz, 1H), 7.52 (dd, $J = 8.8, 2.3$ Hz, 1H), 7.35-7.38 (m, 2H), 7.26-7.31 (m, 2H), 7.20-7.25 (m, 1H), 6.95 (d, $J = 8.8$ Hz, 1H), 3.31 (d, $J = 16.8$ Hz, 1H), 3.07 (d, $J = 16.4$ Hz, 1H), 1.74 (s, 3H); $^{13}\text{C-NMR}$ (101 MHz, CDCl_3) δ 190.5, 159.0, 142.4, 138.8, 129.2, 128.8, 128.0, 125.3, 122.4, 120.5, 113.8, 83.0, 47.7, 30.2;

IR $\nu = 3673, 2975, 2901, 1696, 1598, 1467, 1416, 1266, 1230, 1176, 1133, 1079, 1045, 954, 897, 825, 762, 700 \text{ cm}^{-1}$; HRMS (EI) calc'd for $\text{C}_{16}\text{H}_{13}\text{BrO}_2$ [$\text{M}]^+$: 316.0099, found: 316.0092; $[\alpha]_D^{25} +33.3$ (c 0.63, CHCl_3); HPLC Conditions: 5% IPA/ Hexanes, 1.0 mL/min, Daicel Chiralpak ID column, $\lambda = 220$ nm, t_R (min): major = 7.03, minor = 7.75, 99% ee.



5. References

1. D. Zhao, B. Beiring, F. Glorius, *Angew. Chem. Int. Ed.* 2013, **52**, 8454.
2. J. L. Vicario, D. Badia, L. Carrillo, *Arkivoc*, 2007, 304.
3. A. L. Gerten, L. M. Stanley, *Tetrahedron Lett.* 2016, **57**, 5460.

6. X-Ray Analysis for Compound 6e and [(S)-3d]PdCl₂

An X-Ray quality single crystal of compound **6e** was obtained by slow recrystallization from hexane solution (76 mg/700 μL) at 25 °C. Weak argon blowing helps to make seed in the solution. An X-ray quality single crystal of [(S)-3d]PdCl₂ was obtained by following recrystallization method. To a solution of [(S)-3d]PdCl₂ (50 mg) in DCM (0.1 mL), diethyl ether (10 mL) was added slowly to make bilayer system. Reflection data for **6e** and [(S)-3d]PdCl₂ were collected on a Bruker APEX-II CCD-based diffractometer with graphite-monochromated MoKα radiation ($\lambda = 0.71073 \text{ \AA}$).




Figure S1. X-Ray Coordinate of Compound 6e

Table S1. X-Ray Crystal Data and Structure Refinement for Compound 6e

Identification code	6e
CCDC number	1954885
Empirical formula	C ₂₀ H ₂₂ O ₂
Formula weight	294.37
Temperature	296(2) K
Wavelength	0.71073 Å
Crystal system	Triclinic
Space group	C2
Unit cell dimensions	a=23.2747(4) Å $\alpha = 90^\circ$ b=6.77810(10) Å $\beta = 91.9349(17)^\circ$ c=10.2443(2) Å $\gamma = 90^\circ$
Volume	1615.20(5) Å ³
Z	4
Density (calculated)	1.211 mg/m ³
Absorption coefficient	0.076 mm ⁻¹
F(000)	632
Theta range for data collection	2.61° to 25.42°
Index ranges	-28≤h≤28, -8≤k≤8, -12≤l≤12
Reflections collected	12536
Independent reflections	2965 [R(int)=0.0180]
Completeness to theta =	99.4%
Data / restraints / parameters	2965/1/203
Goodness-of-fit on F ²	1.043
Final R indices [I > 2σ(I)]	R1 = 0.0306, wR2 = 0.0793[2880]
R indices (all data)	R1 = 0.0315, wR2 = 0.0802
Absolute structure parameter	0.0(2)
Largest diff. peak and hole	0.147 and -0.182 e·Å ⁻³

Table S2. Bond lengths[\AA] and angles[$^\circ$] for compound 6e

O1-C1	1.216(2)
O2-C3	1.367(2)
O2-C4	1.457(2)
C1-C2	1.475(3)
C1-C5	1.506(3)
C2-C3	1.400(2)
C2-C6	1.401(3)
C3-C9	1.389(3)
C4-C10	1.524(2)
C4-C5	1.526(3)
C4-C11	1.530(2)
C6-C7	1.377(3)
C7-C8	1.393(3)
C8-C9	1.386(3)
C11-C16	1.386(2)
C11-C12	1.387(3)
C12-C13	1.388(3)
C13-C14	1.390(3)
C14-C15	1.387(3)
C14-C17	1.538(2)
C15-C16	1.389(3)
C17-C20	1.519(3)
C17-C19	1.530(3)
C17-C18	1.537(3)
C3-O2-C4	116.87(12)
O1-C1-C2	123.18(18)
O1-C1-C5	122.50(18)
C2-C1-C5	114.26(16)
C3-C2-C6	118.66(17)
C3-C2-C1	119.77(16)
C6-C2-C1	121.46(16)
O2-C3-C9	116.42(15)

O2-C3-C2	122.90(16)
C9-C3-C2	120.66(16)
O2-C4-C10	103.81(14)
O2-C4-C5	108.49(13)
C10-C4-C5	111.36(16)
O2-C4-C11	109.21(14)
C10-C4-C11	109.83(14)
C5-C4-C11	113.65(14)
C1-C5-C4	111.86(16)
C7-C6-C2	121.02(17)
C6-C7-C8	119.38(17)
C9-C8-C7	120.88(18)
C8-C9-C3	119.38(16)
C16-C11-C12	117.40(16)
C16-C11-C4	121.96(16)
C12-C11-C4	120.39(16)
C11-C12-C13	120.96(18)
C12-C13-C14	122.04(19)
C15-C14-C13	116.52(17)
C15-C14-C17	122.14(15)
C13-C14-C17	121.21(17)
C14-C15-C16	121.74(16)
C11-C16-C15	121.31(17)
C20-C17-C19	108.34(18)
C20-C17-C18	109.30(18)
C19-C17-C18	108.22(17)
C20-C17-C14	112.37(16)
C19-C17-C14	111.19(15)
C18-C17-C14	107.32(15)




Figure S2. X-Ray Coordinate of [(S)-3d]PdCl₂

Table S3. X-ray crystal data and structure refinement for [(S)-3d]PdCl₂

Identification code	[(S)-3d]PdCl ₂		
CCDC number	1843946		
Empirical formula	C ₂₇ H ₂₇ Cl ₄ F ₃ N ₂ Pd		
Formula weight	684.71		
Temperature	296(2)	K	
Wavelength	0.71073 Å		
Crystal system	Triclinic		
Space group	Orthohombic		
P2 ₁ 2 ₁ 2 ₁			
Unit cell dimensions	a=7.3222(2) Å	α = 90°	
	b=16.3645(5) Å	β = 90°	
	c=22.9119(6) Å	γ = 90°	
Volume	2745.40(13) Å ³		
Z	4		
Density (calculated)	1.657 mg/m ³		
Absorption coefficient	1.104 mm ⁻¹		
F(000)	1272		
Theta range for data collection	2.17° to 19.77°		
Index ranges	-8≤h≤8, -19≤k≤19, -27≤l≤27		
Reflections collected	37246		
Independent reflections	5004 [R(int)=0.0716]		
Completeness to theta =	99.7%		
Data / restraints / parameters	5004/0/336		
Goodness-of-fit on F ²	0.996		
Final R indices [I > 2σ(I)]	R1 = 0.0441, wR2 = 0.0932[3907]		
R indices (all data)	R1 = 0.0676, wR2 = 0.1018		
Absolute structure parameter	-0.04(2)		
Largest diff. peak and hole	0.689 and -0.472 e·Å ⁻³		

Table S4. Bond lengths[\AA] and angles[$^\circ$] for [(S)-3d]PdCl₂

Pd1-N2	2.017(5)
Pd1-N1	2.024(6)
Pd1-Cl2	2.2800(18)
Pd1-Cl1	2.2870(17)
N1-C5	1.313(9)
N1-C1	1.361(8)
N2-C7	1.301(9)
N2-C11	1.479(9)
C12-C13	1.387(10)
C12-C8	1.398(10)
C15-C9	1.381(9)
C15-C14	1.395(10)
C14-C13	1.394(10)
C7-C1	1.474(9)
C7-C8	1.475(9)
C8-C9	1.403(10)
C9-C10	1.492(10)
C1-C2	1.379(10)
C11-C10	1.515(10)
C11-C16	1.562(10)
C17-C22	1.385(11)
C17-C18	1.418(11)
C17-C16	1.524(9)
C22-C21	1.410(10)
C22-C25	1.503(11)
C21-C20	1.371(12)
C19-C20	1.360(12)
C19-C18	1.398(11)
C18-C23	1.518(11)
C4-C5	1.373(10)
C4-C3	1.375(10)
C4-C6	1.498(10)

C3-C2	1.384(10)
C26-C25	1.527(11)
C24-C23	1.515(11)
C6-F1	1.334(10)
C6-F3	1.335(8)
C6-F2	1.342(10)
Cl3-C27	1.723(13)
Cl4-C27	1.765(12)
N2-Pd1-N1	80.1(2)
N2-Pd1-Cl2	95.34(17)
N1-Pd1-Cl2	175.41(18)
N2-Pd1-Cl1	174.39(16)
N1-Pd1-Cl1	94.30(16)
Cl2-Pd1-Cl1	90.27(8)
C5-N1-C1	119.0(6)
C5-N1-Pd1	127.2(5)
C1-N1-Pd1	113.7(5)
C7-N2-C11	118.2(5)
C7-N2-Pd1	115.3(5)
C11-N2-Pd1	126.5(4)
C13-C12-C8	119.9(7)
C9-C15-C14	121.2(7)
C13-C14-C15	119.4(7)
N2-C7-C1	115.5(6)
N2-C7-C8	121.9(6)
C1-C7-C8	122.6(6)
C12-C8-C9	120.2(6)
C12-C8-C7	122.9(7)
C9-C8-C7	116.6(6)
C15-C9-C8	118.9(7)
C15-C9-C10	124.7(7)
C8-C9-C10	116.3(6)
C12-C13-C14	120.1(7)

N1-C1-C2	120.9(6)
N1-C1-C7	114.4(6)
C2-C1-C7	124.4(6)
N2-C11-C10	109.8(6)
N2-C11-C16	109.5(6)
C10-C11-C16	114.7(6)
C9-C10-C11	109.8(6)
C22-C17-C18	119.4(7)
C22-C17-C16	121.2(7)
C18-C17-C16	119.4(7)
C17-C16-C11	111.9(6)
C17-C22-C21	119.3(8)
C17-C22-C25	123.3(7)
C21-C22-C25	117.4(8)
C20-C21-C22	121.3(8)
C20-C19-C18	122.7(9)
C19-C18-C17	118.0(7)
C19-C18-C23	121.4(8)
C17-C18-C23	120.6(7)
C19-C20-C21	118.8(9)
C5-C4-C3	119.1(7)
C5-C4-C6	121.6(6)
C3-C4-C6	119.3(7)
C4-C3-C2	118.8(7)
C1-C2-C3	119.2(7)
N1-C5-C4	122.9(7)
C24-C23-C18	116.8(8)
C22-C25-C26	112.6(7)
F1-C6-F3	107.0(7)
F1-C6-F2	106.8(6)
F3-C6-F2	105.9(7)
F1-C6-C4	111.8(7)
F3-C6-C4	112.5(7)

F2-C6-C4 112.4(7)

Cl3-C27-Cl4 112.4(5)

7. NMR Spectra for Compounds

